Remember meForgot password?
    Log in with Twitter

article imageNew medical cannabis chewing gum set for launch

By Tim Sandle     Mar 2, 2017 in Health
A new cannabis chewing gum is in development by the biotechnology company AXIM Biotechnologies. The new product will be branded CanChew Plus and it is an advancement on gum already on the market.
AXIM Biotechnologies currently produces a cannabis gum called CanChew. This was the world’s first patented controlled-release cannabinoid chewing gum. The follow-up product is to be called CanChew Plus. The new product is undergoing trials in the Netherlands (for irritable bowel syndrome) and it has been released in the U.S.
The new product contains 10 microgramss of cannabidiol. This is part of the cannabis plant that does not induce the feelings of euphoria. Cannabidiol is one of at 113 identified active cannabinoids in cannabis, accounting for around 40 percent of the typical extract from the plant. Cannabidiol is the constituent that has the greatest scope for medical applications. One medical application is Dravet syndrome, which is a rare form of epilepsy that is difficult to treat. A secondary area of research is with the treatment of psychosis.
The new product releases cannabidiol via a patented delivery system. This is based on microencapsulation, a process that controls the release of cannabidiol over time, allowing for maximum absorption. Microencapsulation renders cannabinoids soluble and dramatically increases the bioavailability of the active ingredient.
The key difference between the CanChew Plus product and the previous version of the gum is the size, with the new gum being 60 percent smaller. The size has been reduced to improve the chewing experience.
As to the taste, the person who chews the gum experiences a spearmint flavor (there are no artificial sweeteners or animal products). Because the addictive part of cannabis, which gives the high, is not present the use of the gum is non-habit forming. In parts of the world where medical cannabis is legal, such as is most of the U.S., no prescriptions are needed (in other parts of the world this will depend on the status of medical marijuana use).
Discussing the U.S. launch of the new product, the head of AXIM Biotech , George E. Anastassov, said in communication to Digital Journal: “We are excited to introduce the new and improved version of our popular controlled release cannabidiol chewing gum.”
He continues: “With patented microencapsulation technologies, the new products will offer higher absorption rate and more predictable delivery of our hemp oil extracted cannabidiol.”
More about Cannabis, Chewing gum, Marijuna
More news from
Latest News
Top News